Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Product information and disease descriptionProduct descriptionProduct information

Contraindications/Warnings/Precautions/Adverse effects

15 evidence topics · 12 sources

Warnings and precautions
Approved prescribing information, boxed warnings, contraindications, and REMS

Not applicable.

Subcutaneous formulation: adverse events of special interest and treatment discontinuation by dose in the phase 2 trial
Event, n (%)Placebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
TEAE leading to treatment discontinuation“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote
Treatment-emergent serious adverse events“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote
Pancreatitis“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Gallbladder associated events“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote
Injection site reactions“3 (9)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Oral formulation: serious and drug-related adverse events by cohort in the phase 1 multiple ascending dose study
Event, number of subjects (%)Placebo (n=19)2.5 mg (n=8)5 mg (n=7)10 mg (n=6)20 mg (n=8)40 mg (n=8)60 mg (n=9)80 mg A (n=9)80 mg B (n=9)100 mg (n=9)
Drug related TEAEs“11 (58%)”“4 (50%)”“4 (57%)”“3 (50%)”“4 (50%)”“7 (88%)”“6 (67%)”“9 (100%)”“7 (78%)”“9 (100%)”
Serious adverse events“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“1 (11%)”“0 (0%)”“0 (0%)”“0 (0%)”